The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen
signaling. Androgen deprivation therapy and second-generation androgen receptor (AR) …
signaling. Androgen deprivation therapy and second-generation androgen receptor (AR) …
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
MP Labrecque, IM Coleman, LG Brown… - The Journal of …, 2019 - Am Soc Clin Investig
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …
Metastatic castration-resistant prostate cancer remains dependent on oncogenic drivers found in primary tumors
PURPOSE Metastatic prostate cancer is initially sensitive to androgen receptor inhibition,
but eventually becomes castration-resistant prostate cancer (mCRPC). Early use of more …
but eventually becomes castration-resistant prostate cancer (mCRPC). Early use of more …
Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing
Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer
(mCRPC), but there have been few whole-genome sequencing (WGS) studies of this …
(mCRPC), but there have been few whole-genome sequencing (WGS) studies of this …
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer
Men with metastatic prostate cancer who are treated with androgen deprivation therapies
(ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant …
(ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant …
[HTML][HTML] Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy
P Rajan, IM Sudbery, MEM Villasevil, E Mui, J Fleming… - European urology, 2014 - Elsevier
Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced
or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration …
or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration …
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer
TW Friedlander, R Roy, SA Tomlins, VT Ngo… - Cancer research, 2012 - AACR
Progression of primary prostate cancer to castration-resistant prostate cancer (CRPC) is
associated with numerous genetic and epigenetic alterations that are thought to promote …
associated with numerous genetic and epigenetic alterations that are thought to promote …
Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations
that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss …
that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss …
Biological evolution of castration-resistant prostate cancer
Context Recent studies focused on the molecular characterization of metastatic prostate
cancer have identified genomic subsets and emerging resistance patterns. Detection of …
cancer have identified genomic subsets and emerging resistance patterns. Detection of …
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR)
dependence leads to clinically aggressive tumors with few therapeutic options. We used …
dependence leads to clinically aggressive tumors with few therapeutic options. We used …
相关搜索
- therapeutic targets prostate cancers
- prostate cancer changes in the genome
- prostate cancer androgen deprivation
- chromatin profiles prostate cancers
- prostate cancer oncogenic drivers
- prostate cancer transcriptome sequencing
- prostate cancer primary tumors
- prostate cancer biological evolution
- prostate cancer structural alterations
- prostate cancer genome sequencing
- prostate cancer molecular profiling